Institutional & Insider Ownership
56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 61.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by institutional investors. 39.3% of Mangoceuticals shares are owned by company insiders. Comparatively, 28.0% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Mangoceuticals and its rivals top-line revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Mangoceuticals | $866,792.00 | -$9.21 million | -0.38 |
Mangoceuticals Competitors | $2.48 billion | $61.83 million | 10.79 |
Mangoceuticals’ rivals have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Mangoceuticals | -1,053.93% | -243.34% | -200.73% |
Mangoceuticals Competitors | -742.62% | -46.59% | -34.59% |
Volatility & Risk
Mangoceuticals has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500. Comparatively, Mangoceuticals’ rivals have a beta of 3.73, suggesting that their average stock price is 273% more volatile than the S&P 500.
Summary
Mangoceuticals rivals beat Mangoceuticals on 8 of the 9 factors compared.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.